Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03639363
Other study ID # Duclorexint
Secondary ID
Status Completed
Phase Phase 4
First received
Last updated
Start date August 10, 2015
Est. completion date May 2, 2016

Study information

Verified date August 2018
Source University Of Perugia
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The study will assess the utility of 4% chlorhexidine gluconate (CHG) daily bathing to reduce hospital acquired infections in patients admitted to intensive care units. One group will be daily bathed with 4% CHG and the other group with standard soap.


Recruitment information / eligibility

Status Completed
Enrollment 449
Est. completion date May 2, 2016
Est. primary completion date April 28, 2016
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria:

- admission to the intensive care unit (ICU) or to the post-operative cardiosurgical ICU (PC-ICU)

- ICU/PC-ICU stay for at least 1 night

Exclusion Criteria:

- known allergy to chlorhexidine

- burns, toxic epidermal necrolysis or Stevens-Johnson syndrome as admission diagnosis

- pregnancy

Study Design


Intervention

Drug:
4% chlorhexidine gluconate soap-like solution
humidify the whole body surface with the exception of the face using water-impregnated washcloths use 4% CHG-impregnated washcloths to bath the whole body surface with the exception of the face; use at least 30 ml of 4% CHG wait for at least 30 seconds rinse using water-impregnated washcloths
Other:
standard soap
humidify the whole body surface with the exception of the face using water-impregnated washcloths use standard soap-impregnated washcloths to bath the whole body surface with the exception of the face wait for at least 30 seconds rinse using water-impregnated washcloths

Locations

Country Name City State
n/a

Sponsors (2)

Lead Sponsor Collaborator
University Of Perugia Fondazione Toscana Gabriele Monasterio

Outcome

Type Measure Description Time frame Safety issue
Primary hospital acquired infections incidence cumulative incidence of bloodstream infections (BSI), central line-associates BSI (CLABSI), urinary tract infections (UTI), catheter-associated UTI (CAUTI) and ventilator-associated pneumonias (VAP) infections occured 48 hours after admission to ICU/PC-ICU
Secondary Ventilator-associated pnemonias (VAP) incidence VAP incidence infections occured 48 hours after admission to ICU/PC-ICU
Secondary Bloodstream infections (BSI) incidence BSI incidence infections occured 48 hours after admission to ICU/PC-ICU
Secondary central-line associated BSI (CLABSI) incidence CLABSI incidence infections occured 48 hours after admission to ICU/PC-ICU
Secondary urinary tract infections (UTI) incidence UTI incidence infections occured 48 hours after admission to ICU/PC-ICU
Secondary catheter associated UTI (CAUTI) incidence CAUTI incidence infections occured 48 hours after admission to ICU/PC-ICU
Secondary 4% CHG daily bathing safety overall mortality in the treatment and control arm at discharge, approximately up to 10 days
Secondary 4% CHG daily bathing-related adverse events 4% CHG daily bathing-related adverse events in the treatment arm compared to standard soap-related adverse events at discharge, approximately up to 10 days
Secondary time till infection time between admission to ICU/PC-ICU and infection occurrence at discharge, approximately up to 10 days
See also
  Status Clinical Trial Phase
Recruiting NCT03665467 - The Global Prevalence of Infections in Urology Study
Not yet recruiting NCT06430073 - Effect of Infections and Global DNA Methylation on Frailty Trajectories in Hospitalized Older Patients (INFRAGEN)
Active, not recruiting NCT04328818 - Indwelling Device-associated Biofilms
Recruiting NCT04995133 - Colistin Intravenous Administration in Critically Ill Patients Suffering From Hospital Infections Caused by Multi-antibiotic-resistant Germs. Phase 4
Not yet recruiting NCT06103500 - Integrated Clinical Decision Support for Empiric Antibiotic Selection in Sepsis N/A
Completed NCT06199804 - Toy Hygiene Education For Hospitalized Mothers N/A
Recruiting NCT04920240 - Application of Standardized Cleaning and Disinfection Mode of HFT Surface in Hospital Infection Prevention and Control N/A
Recruiting NCT02328183 - Efficacy of Polymyxin B Against Infections Caused by Extensively Drug-resistant (XDR) Gram-Negative Bacteria Phase 4